LXRX
$1.56-0.06 (-3.70%)
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.
Recent News
H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is one of the High-Flying Penny Stocks to Buy. On March 12, H.C. Wainwright reiterated a Buy rating on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) with a $6 price target. The analyst noted positive post-hoc analyses of sotagliflozin, which showed cardiometabolic benefits such as reduction in HbA1c, body weight, systolic blood pressure, and […]
H.C. Wainwright Raises its Price Target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and Maintains a Buy Rating
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On March 5, 2026, H.C. Wainwright raised the price target on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to $6 from $4 previously and maintained a Buy rating following the company’s fourth-quarter report. H.C. Wainwright increased the probability of success for pilavapadin […]
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
Xenon stock soars after phase III X-TOLE2 shows azetukalner significantly cuts focal onset seizure frequency. The company plans an NDA filing in third-quarter 2026.
Lexicon Pharmaceuticals Q4 Earnings Call Highlights
Lexicon Pharmaceuticals (NASDAQ:LXRX) outlined progress across three late-stage programs and reported sharply lower operating expenses during its fourth-quarter and full-year 2025 earnings call held March 5, 2026. Management emphasized near-term regulatory and clinical milestones for sotagliflozin i
Lexicon Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Moby summary of Lexicon Pharmaceuticals, Inc.'s Q4 2025 earnings call